Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model

Kamposioras,Konstantinos; Tsimplouli,Chrysiida; Verbeke,Caroline; Anthoney,Alan; Daoukopoulou,Argyro; Papandreou,Christos N.; Sakellaridis,Nikolaos; Vassilopoulos,George; Potamianos,Spyros P.; Liakouli,Vasiliki; Migneco,Gemma; Del Galdo,Francesco; Dimas,Konstantinos

doi:10.3892/ijo.2018.4640

Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model

Authors:
- Konstantinos Kamposioras
- Chrysiida Tsimplouli
- Caroline Verbeke
- Alan Anthoney
- Argyro Daoukopoulou
- Christos N. Papandreou
- Nikolaos Sakellaridis
- George Vassilopoulos
- Spyros P. Potamianos
- Vasiliki Liakouli
- Gemma Migneco
- Francesco Del Galdo
- Konstantinos Dimas
View Affiliations

Affiliations: Department of Medical Oncology, The Mid Yorkshire Hospitals NHS Trust, WF1 4DG Wakefield, UK, Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41500 Larissa, Greece, Institute of Clinical Medicine, University of Oslo, Norway, Department of Medical Oncology, The Leeds Teaching Hospitals NHS Trust, LS9 7TF Leeds, UK, Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece, Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece, Department of Gastroenterology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece, Scleroderma Programme, Leeds Institute of Rheumatic and Musculoskeletal Medicine, LMBRU, University of Leeds, LS9 7TF Leeds, UK, Division of Oncology, Leeds Institute of Molecular Medicine, St. James's University Hospital Leeds, LS9 7TF Leeds, UK
Published online on: November 21, 2018 https://doi.org/10.3892/ijo.2018.4640
Pages: 537-549
Copyright: © Kamposioras et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Caveolin‑1 (Cav‑1) expression has been shown to be associated with tumor growth and resistance to chemotherapy in pancreatic cancer. The primary aim of this study was to explore the significance of Cav‑1 expression in pancreatic cancer cells as compared to fibroblasts in relation to cancer cell proliferation and chemoresistance, both in vitro and in vivo, in an immunodeficient mouse model. We also aimed to evaluate the immunohistochemical expression of Cav‑1 in the epithelial and stromal component of pancreatic cancer tissue specimens. The immunohistochemical staining of poorly differentiated tissue sections revealed a strong and weak Cav‑1 expression in the epithelial tumor cells and stromal fibroblasts, respectively. Conversely, the well‑differentiated areas were characterized by a weak epithelial Cav‑1 expression. Cav‑1 downregulation in cancer cells resulted in an increased proliferation in vitro; however, it had no effect on chemoresistance and growth gain in vivo. By contrast, the decreased expression of Cav‑1 in fibroblasts resulted in a growth advantage and the chemoresistance of cancer cells when they were co‑injected into immunodeficient mice to develop mixed fibroblast/cancer cell xenografts. On the whole, the findings of this study suggest that the downregulation of Cav‑1 in fibroblasts is associated with an increased tumor proliferation rate in vivo and chemoresistance. Further studies are warranted to explore whether the targeting of Cav‑1 in the stroma may represent a novel therapeutic approach in pancreatic cancer.

View Figures

View References

1	Malvezzi M, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2014. Ann Oncol. 25:1650–1656. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al: ESMO Guidelines Committee: Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5): v56–v68. 2015. View Article : Google Scholar
3	Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W and Sandvold ML: Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scand J Gastroenterol. 44:782–786. 2009. View Article : Google Scholar : PubMed/NCBI
4	Williams TM and Lisanti MP: The Caveolin genes: From cell biology to medicine. Ann Med. 36:584–595. 2004. View Article : Google Scholar
5	Chen T, Liu L, Xu HX, Wang WQ, Wu CT, Yao WT and Yu XJ: Significance of caveolin-1 regulators in pancreatic cancer. Asian Pac J Cancer Prev. 14:4501–4507. 2013. View Article : Google Scholar : PubMed/NCBI
6	Boscher C and Nabi IR: Caveolin-1: Role in cell signaling. Adv Exp Med Biol. 729:29–50. 2012. View Article : Google Scholar
7	Del Pozo MA and Schwartz MA: Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends Cell Biol. 17:246–250. 2007. View Article : Google Scholar
8	Wary KK, Mariotti A, Zurzolo C and Giancotti FG: A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 94:625–634. 1998. View Article : Google Scholar : PubMed/NCBI
9	Goetz JG, Lajoie P, Wiseman SM and Nabi IR: Caveolin-1 in tumor progression: The good, the bad and the ugly. Cancer Metastasis Rev. 27:715–735. 2008. View Article : Google Scholar
10	Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, et al: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer. 87:1140–1144. 2002. View Article : Google Scholar
11	Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, et al: Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Histol. 40:23–29. 2009. View Article : Google Scholar
12	Nam KH, Lee BL, Park JH, Kim J, Han N, Lee HE, Kim MA, Lee HS and Kim WH: Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer. Pathobiology. 80:87–94. 2013. View Article : Google Scholar
13	Han F, Zhang J, Shao J and Yi X: Caveolin-1 promotes an invasive phenotype and predicts poor prognosis in large cell lung carcinoma. Pathol Res Pract. 210:514–520. 2014. View Article : Google Scholar
14	Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, Sugito N, Tomoda K, Mori R, Harada K, Katada T, et al: The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep. 18:601–609. 2007.
15	Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, Le X, Wei D, Huang S and Xie K: A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res. 72:655–665. 2012. View Article : Google Scholar
16	Lin M, DiVito MM, Merajver SD, Boyanapalli M and van Golen KL: Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. Mol Cancer. 4:212005. View Article : Google Scholar : PubMed/NCBI
17	Ye Y, Miao SH, Lu RZ and Zhou JW: Prognostic value of caveolin-1 expression in gastric cancer: A meta-analysis. Asian Pac J Cancer Prev. 15:8367–8370. 2014. View Article : Google Scholar
18	Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR and Lisanti MP: An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 174:2023–2034. 2009. View Article : Google Scholar
19	Ma X, Liu L, Nie W, Li Y, Zhang B, Zhang J and Zhou R: Prognostic role of caveolin in breast cancer: A meta-analysis. Breast. 22:462–469. 2013. View Article : Google Scholar
20	Zhao Z, Han FH, Yang SB, Hua LX, Wu JH and Zhan WH: Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival. World J Gastroenterol. 21:1140–1147. 2015. View Article : Google Scholar : PubMed/NCBI
21	Shan T, Lu H, Ji H, Li Y, Guo J, Chen X and Wu T: Loss of stromal caveolin-1 expression: A novel tumor microenvironment biomarker that can predict poor clinical outcomes for pancreatic cancer. PLoS One. 9:e972392014. View Article : Google Scholar : PubMed/NCBI
22	Jia Y, Wang N, Wang J, Tian H, Ma W, Wang K, Tan B, Zhang G, Yang S, Bai B, et al: Down-regulation of stromal caveolin-1 expression in esophageal squamous cell carcinoma: A potent predictor of lymph node metastases, early tumor recurrence, and poor prognosis. Ann Surg Oncol. 21:329–336. 2014. View Article : Google Scholar
23	Zhao X, He Y, Gao J, Fan L, Li Z, Yang G and Chen H: Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer. PLoS One. 8:e591022013. View Article : Google Scholar
24	Nakatani K, Wada T, Nakamura M, Uzawa K, Tanzawa H and Fujita S: Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 131:445–452. 2005. View Article : Google Scholar
25	Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S and Notario V: Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing’s sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer. 126:426–436. 2010. View Article : Google Scholar
26	Wang Z, Wang N, Liu P, Peng F, Tang H, Chen Q, Xu R, Dai Y, Lin Y, Xie X, et al: Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget. 6:37135–37150. 2015.PubMed/NCBI
27	Hehlgans S and Cordes N: Caveolin-1: An essential modulator of cancer cell radio-and chemoresistance. Am J Cancer Res. 1:521–530. 2011.
28	Hehlgans S, Eke I, Storch K, Haase M, Baretton GB and Cordes N: Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells. Radiother Oncol. 92:362–370. 2009. View Article : Google Scholar
29	Salem AF, Bonuccelli G, Bevilacqua G, Arafat H, Pestell RG, Sotgia F and Lisanti MP: Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle. 10:3692–3700. 2011. View Article : Google Scholar
30	Witkiewicz AK, Nguyen KH, Dasgupta A, Kennedy EP, Yeo CJ, Lisanti MP and Brody JR: Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: Implications for tumor progression and clinical outcome. Cell Cycle. 7:3021–3025. 2008. View Article : Google Scholar
31	Dimas K, Hatziantoniou S, Tseleni S, Khan H, Georgopoulos A, Alevizopoulos K, Wyche JH, Pantazis P and Demetzos C: Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. Apoptosis. 12:685–694. 2007. View Article : Google Scholar
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
33	Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, Trent JM, Staudt LM, Hudson J Jr, Boguski MS, et al: The transcriptional program in the response of human fibroblasts to serum. Science. 283:83–87. 1999. View Article : Google Scholar
34	Tsimplouli C, Demetzos C, Hadzopoulou-Cladaras M, Pantazis P and Dimas K: In vitro activity of dietary flavonol congeners against human cancer cell lines. Eur J Nutr. 51:181–190. 2012. View Article : Google Scholar
35	Dimas K, Demetzos C, Vaos B, Marselos M and Kokkinopoulos D: Cytotoxic and antiproliferative effects of heptaacetyltiliroside on human leukemic cell lines. Leuk Res. 23:1021–1033. 1999. View Article : Google Scholar
36	Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, et al: Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep. 5:108672015. View Article : Google Scholar :
37	Alshenawy HA and Ali MA: Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin-β-catenin complex. Ann Diagn Pathol. 17:476–482. 2013. View Article : Google Scholar
38	Erkan M, Kurtoglu M and Kleeff J: The role of hypoxia in pancreatic cancer: A potential therapeutic target. Expert Rev Gastroenterol Hepatol. 10:301–316. 2016. View Article : Google Scholar
39	Verbeke C: Morphological heterogeneity in ductal adenocarcinoma of the pancreas - Does it matter. Pancreatology. 16:295–301. 2016. View Article : Google Scholar : PubMed/NCBI
40	Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA and Mulvihill SJ: Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 39:425–435. 2010. View Article : Google Scholar
41	Han F and Zhu HG: Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. J Surg Res. 159:443–450. 2010. View Article : Google Scholar
42	Cordes N, Frick S, Brunner TB, Pilarsky C, Grützmann R, Sipos B, Klöppel G, McKenna WG and Bernhard EJ: Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene. 26:6851–6862. 2007. View Article : Google Scholar : PubMed/NCBI
43	Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR and Lisanti MP: An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 8:2420–2424. 2009. View Article : Google Scholar
44	Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, et al: Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 9:2423–2433. 2010. View Article : Google Scholar
45	Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, et al: The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle. 9:1960–1971. 2010. View Article : Google Scholar : PubMed/NCBI
46	Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, et al: Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the ‘reverse Warburg effect’: A transcriptional informatics analysis with validation. Cell Cycle. 9:2201–2219. 2010. View Article : Google Scholar
47	Capozza F, Trimmer C, Castello-Cros R, Katiyar S, Whitaker- Menezes D, Follenzi A, Crosariol M, Llaverias G, Sotgia F, Pestell RG, et al: Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice: Role of Cav1 in Shh heterotypic signaling and transendothelial migration. Cancer Res. 72:2262–2274. 2012. View Article : Google Scholar
48	Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar
49	Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25:719–734. 2014. View Article : Google Scholar
50	Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al: Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 25:735–747. 2014. View Article : Google Scholar
51	Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, et al: Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 67:497–507. 2018. View Article : Google Scholar :
52	Bocci G, Fioravanti A, Orlandi P, Di Desidero T, Natale G, Fanelli G, Viacava P, Naccarato AG, Francia G and Danesi R: Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombos-pondin-1 and down-regulation of cyclin D1. Neoplasia. 14:833–845. 2012. View Article : Google Scholar
53	Ma Y, Lin Z, Fallon JK, Zhao Q, Liu D, Wang Y and Liu F: New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer. Oncol Rep. 34:2699–2705. 2015. View Article : Google Scholar